Amarin Corp Plc (AMRN)

[biowreck]

Main...obviously there is no guarantee but here's some credible evidence regarding RRR. posted in aug 17

This past Sunday, at the European Society of Cardiology (ESC) Congress, Novartis posted a data read-out from its pivotal Phase 3 CANTOS trial assessing quarterly injections of ACZ885 (canakinumab) in people with a prior heart attack and inflammatory atherosclerosis. The results? Participants experienced a reduction in inflammation under the median hsCRP, an indicated 27% relative risk on primary MACE end-point.

This begs the following question: How exactly does Amarin Corporation plc (ADR) (NASDAQ:AMRN) fall into the cardiovascular therapy mix of Novartis’ results?

According to Cantor analyst Louise Chen, a great deal, as she trumpets, pay attention to “this catch of the day,” for the outcome proves her bullish contention: a long-term drug treatment with an anti-inflammatory mechanism in patients who have once had a heart attack and inflammatory atherosclerosis can offer a reduction of cardiovascular (CV) events. In other words, Novartis has just bolstered Chen’s conviction in Amarin’s REDUCE-IT (Reduction of Cardiovascular Events Outcomes) to clear the gates to an eventual solid commercial trajectory.